Type 1 and type 2 diabetes, insulin resistance, glucose metabolism, and metabolic health
599 articles
Where muscle stores fat tracked insulin sensitivity, but 12-week lifestyle programs and single exercise sessions barely shifted those patterns.
Fatty liver disease affects roughly one in three adults and usually causes no symptoms. Learn how the liver ages, what MASLD is, and which habits and treatments help.
Adults with type 2 diabetes taking semaglutide or tirzepatide had fewer alcohol-related emergency visits than those taking SGLT2 inhibitors.
GLP-1 drugs tracked with lower cardiovascular risk in patients with fatty liver and diabetes, but additional analyses weakened the finding.
A completed observational study explores metformin and muscle health in older adults with diabetes, but the supplied abstract reports no results.
A large Israeli study links SGLT2 inhibitors to more yeast-positive urine cultures, but not more hospitalizations for urinary infections.
CGMs reveal glucose patterns, but longevity benefits remain unproven. This review weighs device costs, coaching claims, and practical limitations.
UBT251 lowered blood sugar and outperformed 1 mg semaglutide on weight loss over 24 weeks. Larger trials must establish longer-term benefits and safety.
In 260,823 matched pairs, metformin use was linked to 17% lower odds of carpal and cubital tunnel surgery and 29% lower odds of revision surgery.
In obese rats, calorie cutting and low-fat diet swaps raised dyslipidemia and cell stress when a high-fat diet returned. Alternate-day fasting looked safer.
GLP-1 drugs may improve menstrual regularity, but pregnancy safety remains uncertain. Tirzepatide may require backup contraception.
A 2025 review finds roughly a quarter to a third of GLP-1 drug weight loss is lean mass, similar to dieting, but trials rarely test whether muscle function suffers.
